A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 400 KRW 3.79% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-40.7
Current
-24.1
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-40.7
=
Enterprise Value
1.3T KRW
/
EBITDA
-32.6B KRW
All Countries
Close
Market Cap EV/EBITDA
KR
ABL Bio Inc
KOSDAQ:298380
1.3T KRW -40.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 476
US
Abbvie Inc
NYSE:ABBV
310.3B USD 15.2
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 16
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 21
US
Epizyme Inc
F:EPE
94.1B EUR -514.8
AU
CSL Ltd
ASX:CSL
134.4B AUD 19.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 15.1
US
Seagen Inc
F:SGT
39.3B EUR -58.8
NL
argenx SE
XBRU:ARGX
35.7B EUR -108.7
EBITDA Growth EV/EBITDA to Growth
KR
A
ABL Bio Inc
KOSDAQ:298380
Average EV/EBITDA: 16.2
Negative Multiple: -40.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.7 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-30.5
2-Years Forward
EV/EBITDA
-178
3-Years Forward
EV/EBITDA
-36.5

See Also

Discover More